Drug Profile
GP 11
Latest Information Update: 24 May 2001
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Class Antineoplastics
- Mechanism of Action DNA synthesis inhibitors; Immunosuppressants; Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 24 May 2001 Discontinued-Preclinical for Cancer in Japan (Unknown route)
- 09 Jul 1998 Profile reviewed
- 09 Jul 1998 No-Development-Reported for Cancer in Japan (Unknown route)